Stockreport

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals, Inc. - common stock  (ZNTL) 
PDF DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential [Read more]